Contents

Search

albumin/factor IX parenteral; albutrepenonacog alfa (Idelvion)

Indications: - hemophilia B - *as-needed control & prevention of bleeding episodes - *managing perioperative bleeding Pharmacokinetics: - longer 1/2life than recombinant factor IX

General

pharmacologic combination

References

  1. FDA News Release. March 4, 2016 FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm489266.htm